secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001213900-25-057139
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study
------------------------------------------------------------------------------

- INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.
- INM-901 significantly reduced inflammasome marker NLRP3, a key contributor to neurodegeneration.
- Reduction of pro-inflammatory markers independent of amyloid beta or tau pathology.
- Company plans to advance INM-901 through additional preclinical studies with IND-enabling studies to follow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025057139/0001213900-25-057139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025057139/ea0246768-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-057139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer